文献速递肿瘤 PET/CT核素与放射性配体治疗

是否需要18F-FDG PET评估177Lu-PSMA治疗资格?一项类VISION的单中心分析

Is 18F-FDG PET Needed to Assess 177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis.
PubMed 文献 · J Nucl Med · 2022-12-15

本研究回顾性分析89例接受177Lu-PSMA治疗评估的转移性去势抵抗性前列腺癌患者,均行18F-FDG和PSMA PET。按VISION标准仅用PSMA PET重新评估与临床常规(结合两种PET)的一致性为κ=0.73,仅3%患者存在PSMA PET未发现的FDG/PSMA不匹配。

要点

  • 仅用PSMA PET按VISION标准评估与结合18F-FDG的临床评估一致性较高(κ=0.73)。
  • 18%患者存在FDG/PSMA不匹配,但仅3%未被PSMA-only分析发现。
  • 接受177Lu-PSMA治疗者总生存显著长于未治疗者(12.4 vs 6.8个月,P<0.01)。

核心结论

  • 18F-FDG与PSMA PET提供互补信息,但仅用PSMA PET分析未发现的不匹配表现不足5%;基于本研究数据,FDG/PSMA不匹配检查与PSMA-only分析具有高度一致性。

研究设计与样本

  • 单中心分析,纳入2019年6月至2021年10月转诊行177Lu-PSMA治疗的89例转移性去势抵抗性前列腺癌男性,均在2周内完成18F-FDG和PSMA PET(68Ga-PSMA-11或18F-PSMA-1007)。

主要发现

  • 接受177Lu-PSMA治疗的患者总生存显著长于未治疗患者(12.4 vs 6.8个月,P<0.01)。
  • PSMA-only分析(脾/肝参考)与18F-FDG/PSMA不匹配判读具有高度一致性(Cohen κ=0.73)。
  • 18%(16/89)患者基于18F-FDG/PSMA PET存在不匹配表现。
  • 以肝/脾为参考,PSMA-only分析会使3%无不匹配表现(因而接受治疗)的患者被排除治疗。
  • 3%(3例)患者存在PSMA-only(类VISION)分析未发现的18F-FDG/PSMA不匹配表现。

关键数值与推荐

  • 资格判定分别依据临床常规(结合18F-FDG和PSMA PET)或VISION标准仅用PSMA PET(研究再评估,PSMA-11以肝为参考、PSMA-1007以肝/脾为参考,各做两次)。
  • 18F-FDG PET或CT见而PSMA PET未见转移灶定义为不匹配表现,导致排除177Lu-PSMA治疗。

临床怎么用

  • 基于临床评估,52例接受177Lu-PSMA治疗,37例未接受;全部患者均被再评估。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-FDG and prostate-specific membrane antigen (PSMA) PET have been used to assess eligibility for PSMA-targeted therapy by some centers. However, it remains unclear whether both examinations are needed as a part of workup in the clinical practice or whether PSMA PET alone, as was done in the positive phase 3 VISION trial, is sufficient to identify suitable candidates. The aim was to reanalyze all patients who underwent both 18F-FDG and PSMA PET for PSMA-targeted therapy eligibility assessment using the VISION trial criteria. Methods: Eighty-nine men with metastatic castration-resistant prostate cancer referred to 177Lu-PSMA therapy from June 2019 to October 2021 who underwent both 18F-FDG and PSMA PET (using either 68Ga-PSMA-11 or 18F-PSMA-1007) examinations within 2 wk were included in this analysis. Eligibility status was determined in accordance with either knowledge of both 18F-FDG and PSMA PET (clinical routine) or VISION criteria with PSMA PET-only (study reassessment, done twice with liver only for PSMA-11 and liver/spleen as reference for PSMA-1007). A metastasis seen on 18F-FDG PET or CT but not on PSMA PET was denoted as a mismatch finding and led to exclusion from 177Lu-PSMA therapy. On the basis of clinical assessment, 52 patients received 177Lu-PSMA therapy, and 37 did not; all patients were reassessed. Results: Patients treated with 177Lu-PSMA therapy had significantly longer overall survival than those not treated (12.4 vs. 6.8 mo, P < 0.01). PSMA-only analysis (spleen/liver reference) and 18F-FDG/PSMA mismatch reads had substantial agreement (Cohen κ = 0.73). Eighteen percent (n = 16/89) of patients had a mismatch finding based on 18F-FDG/PSMA PET. With the liver/spleen reference, a minor fraction of patients who had no mismatch finding (and were therefore treated) would have been withheld from therapy by PSMA-only analysis (3%). Three percent (n = 3) of all patients had an 18F-FDG/PSMA mismatch finding not detected by PSMA PET-only (VISION-like) analysis. For patients not receiving PSMA therapy, the overall survival was not statistically significantly different comparing 18F-FDG/PSMA mismatch versus nonmismatch (P = 0.61) patients. Conclusion: 18F-FDG and PSMA PET provide complementary information, yet less than 5% of patients had mismatch findings not detected using PSMA PET-only. Based on our data, 18F-FDG/PSMA mismatch examination and PSMA-only analysis have a substantial level of agreement.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Seifert R, Telli T, Hadaschik B, et al. Is 18F-FDG PET Needed to Assess 177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis. J Nucl Med. 2022. PMID: 36522186. doi:10.2967/jnumed.122.264741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。